In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA(R) (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel. The data (ECCO Abstract # 6521)(1) were presented at the 14th European Cancer Conference ECCO) in Barcelona. [click link for full article]
(more...)